Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Oct 28, 2019; 9(6): 134-144
Published online Oct 28, 2019. doi: 10.5500/wjt.v9.i6.134
Published online Oct 28, 2019. doi: 10.5500/wjt.v9.i6.134
Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation
Muhammad A Bukhari, Department of Medicine, Taif University, Taif 26311, Saudi Arabia
Abdulrahman Al-Theaby, Mohammed Tawhari, Department of Transplantation, King Abdulaziz Medical City, Riyadh 11159, Saudi Arabia
Ali Al-Shaggag, Department of Nephrology and Transplantation King Fahad Specialist Hospital, Dammam 15215, Saudi Arabia
Ryan Pyrke, Azim Gangji, Darin Treleaven, Christine Ribic, Department of Nephrology, McMaster University, Hamilton, ON L8N 4A6, Canada
Author contributions: Al-Theaby A, Tawhari M, Al-Shaggag A, Pyrke R, Gangji A, Treleaven D, Bukhari MA, and Ribic C contributed to acquisition of data, analysis and interpretation of data, drafting the article, and final approval; Bukhari MA contributed to conception and design of the study, and critical revision.
Institutional review board statement: The study protocol was reviewed and approved by the Hamilton Integrated Research Ethics Board (www.hireb.ca).
Informed consent statement: This was a retrospective study of anonymized/deidentified medical charts and health records. In consideration of the study design, the Hamilton Integrated Research Ethics Board waived request for informed consent from patients.
Conflict-of-interest statement: The authors deny any conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Muhammad A Bukhari, FRCP, MD, MSc, Assistant Professor, Department of Medicine, Taif University, Taif 26311, Saudi Arabia. bukhary5354@hotmail.com
Telephone: +996-553502550
Received: July 18, 2019
Peer-review started: July 21, 2019
First decision: August 2, 2019
Revised: September 17, 2019
Accepted: October 15, 2019
Article in press: October 15, 2019
Published online: October 28, 2019
Processing time: 101 Days and 10.5 Hours
Peer-review started: July 21, 2019
First decision: August 2, 2019
Revised: September 17, 2019
Accepted: October 15, 2019
Article in press: October 15, 2019
Published online: October 28, 2019
Processing time: 101 Days and 10.5 Hours
Core Tip
Core tip: No consensus is available in the literature about whether novel oral anticoagulants are effective and safe for renal transplant recipients. This is one of the first attempts to investigate the profile, safety and effectiveness of novel oral anticoagulants for adult renal transplant recipients. We investigated the role of novel oral anticoagulants in terms of its effect on thromboembolism, bleeding, creatinine clearance and immunosuppressive agents.